Last reviewed · How we verify
Carnitor (LEVOCARNITINE)
Carnitor (Levocarnitine) is a carnitine analog developed by SIGMA TAU and currently owned by Leadiant Biosci Inc. It targets the liver isoform of Carnitine O-palmitoyltransferase 1, a key enzyme in fatty acid metabolism. FDA-approved in 1985 for treating carnitine deficiency, Carnitor is a small molecule with a half-life of 5 hours and bioavailability of 15%. The drug is off-patent with 7 generic manufacturers available. Key safety considerations include its potential to cause gastrointestinal side effects and interactions with other medications.
At a glance
| Generic name | LEVOCARNITINE |
|---|---|
| Sponsor | Leadiant Biosci Inc |
| Drug class | Carnitine Analog [EPC] |
| Target | Carnitine O-palmitoyltransferase 1, liver isoform |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
| First approval | 1985 |
Approved indications
- Carnitine deficiency
Common side effects
- Seizures
- Nausea
- Vomiting
- Abdominal cramps
- Diarrhea
- Myasthenia
- Body odor
Drug interactions
- warfarin
Key clinical trials
- Effects of Carnitine Supplementation on Exercise-Induced Muscle Damage: A Randomized Controlled Trial (NA)
- Efficacy and Safety of XyloCore Peritoneal Dialysis Solution. (PHASE3)
- CARNIVAL Study: Gut Flora Dependent Metabolism of Dietary CARNItine and Phosphatidylcholine and cardioVAscuLar Disease (EARLY_PHASE1)
- Effect of a Food for Special Medical Purposes on Muscle Mass Preservation During GLP-1 RAs Weight Loss Treatment (NA)
- Impact of CRRT on Serum Carnitine and Micronutrient Levels
- Studying the Effect of Levocarnitine in Protecting the Liver From Chemotherapy for Leukemia or Lymphoma (PHASE3)
- Long-Chain Fatty Acid Oxidation Disorders In-Clinic Disease Monitoring Program
- Effect of L-Carnitine Supplementation in Preterm Neonates (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Carnitor CI brief — competitive landscape report
- Carnitor updates RSS · CI watch RSS
- Leadiant Biosci Inc portfolio CI